Cargando…
Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30–90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, w...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537369/ https://www.ncbi.nlm.nih.gov/pubmed/25947358 http://dx.doi.org/10.1038/jid.2015.145 |